Skip to main content

Table 4 Treatment-related Adverse Events That Occurred in ≥10% of Patients

From: Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

TRAE

Patients Treated With Lenvatinib 24 mg Once Daily (N = 26)

Patients with any-grade TRAE, n (%)

26 (100)

Patients with any TRAE ≥ grade 3, n (%)

16 (61.5)

Preferred term, n (%)

Any grade

Grade 3 or 4

Hypertension

22 (84.6)

10 (38.5)

Dysphonia

16 (61.5)

0

Palmar-plantar erythrodysesthesia syndrome

15 (57.7)

3 (11.5)

Proteinuria

15 (57.7)

3 (11.5)

Thrombocytopenia

13 (50.0)

1 (3.8)

Decreased appetite

12 (46.2)

0

Fatigue

12 (46.2)

0

Hypothyroidism

12 (46.2)

0

Decreased weight

6 (23.1)

0

Diarrhea

6 (23.1)

0

Anemia

5 (19.2)

1 (3.8)

Malaise

5 (19.2)

0

Nausea

5 (19.2)

0

Peripheral edema

5 (19.2)

0

Myalgia

4 (15.4)

0

Stomatitis

4 (15.4)

0

Alopecia

3 (11.5)

0

Constipation

3 (11.5)

0

Epistaxis

3 (11.5)

0

Headache

3 (11.5)

0

Rash

3 (11.5)

1 (3.8)

Upper abdominal pain

3 (11.5)

0

  1. TRAE treatment-related adverse event